NEW YORK (GenomeWeb News) – The National Cancer Institute plans to fund researchers seeking to develop and validate biomarkers that can be used to detect and predict progression of hematopoietic malignancies, such as Hodgkin and non-Hodgkin lymphoma, leukemia, multiple myeloma, and others.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.